099430.KQ BioPlus Co. Ltd.

Healthcare Pharmaceuticals KOSDAQ
3,200 KRW
Close of Oct 31, 2026
3,065 6,439
Market cap
KRW 197B
P/E
15.2x
P/B
1.10x
ROE
9.8%
Dividend yield
2.19%
Fundamental score
2.3/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 099430.KQ undervalued?

Graham number
Price3,200
Graham value3,711
Discount13.8%

099430.KQ trades 13.8% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BioPlus Co. Ltd. fundamental analysis

10 of 22 checks passed

ROE 0/2

Low return on equity (9.8%), below 10%.

ROA 1/1

Return on assets (5.9%) is above the industry median (3.4%).

Profit Consistency 2/2

Profitable for 8 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Last year's EPS growth (-3.0%) is not above the 5-year average (6.9% a year).

Earnings Growth vs Industry 0/1

Last year's EPS growth (-3.0%) is below the industry median (6.6%).

Revenue Growth 2/2

Revenue grew 17.0% a year over the past 3 years.

Short-term Liquidity 0/1

Current assets do not cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (7.6%), 40% or less.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 1/1

Operating cash flow covers 20% of total debt.

Interest Coverage 1/1

EBIT is 79.8x against interest expense, well covered.

PE vs Market 0/1

PE (15.2x) is above the market median (11.3x).

PE vs Industry 1/1

PE (15.2x) is below the industry median (19.4x).

PBV 0/1

Price to book (1.1x) is above the industry median (0.8x).

Graham Number 1/1

The price is below the Graham number (PE x PB = 16.7, limit 22.5).

PEG 0/1

PEG on 5-year earnings growth is 2.19, above 1.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

BioPlus Co. Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BioPlus Co. Ltd.

Bio Plus Co., Ltd engages in the research and development, production, and sale of bio products in South Korea. It offers dermal fillers under the SkinPlus " Hyal, Bio+ Dew, HyalDew, DeneB Classic, Stilea, and 3-Senses brand names. The company also provides medical products, including InterBlock, an absorbable anti-adhesion barrier; Synofil, a synovial fluid replacement; and Blad-Care, a solution to temporarily improve cystitis symptoms. In addition, it offers mesotherapy pr…

Full company profile